Dr. Chung is responsible for developing and executing on the clinical strategy for Kyverna. Prior to Kyverna he was at Amgen where he began in Early Development and served as the Inflammation Therapeutic Area Head. He also worked in late-stage development as the Global Development Leader for Enbrel and as the Inflammation head for the US and Global Medical Organizations. Prior to Amgen he worked in early development, Inflammation, at Pfizer. Dr. Chung obtained his MD and PhD in Immunology at the University of Pennsylvania where he also completed his residency in Internal Medicine and fellowship in Rheumatology.
Track Chair: Sharon Benzeno, Adaptive Biotechnologies